JPRN-C000000141未知未知
A phase II study of Amrubicin in patients with previously treated small cell lung cancer - A phase II study of Amrubicin in patients with previously treated small cell lung cancer
Kinki University School of Medicine0 个研究点目标入组 30 人开始时间: 2005年9月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pregnancy or breast feeding Past history of drug hypersensitivity SVC syndrome Pleural or pericardial effusion that required drainage Active infection Interstitial pneumonia or active lung fibrosis Symptomatic brain metastasis Active concomitant malignancy Uncontrolled diabetes Uncontrolled heart disease
研究者
相似试验
已完成
不适用
Phase 2 study of amrubicin in previously treated patients with malignant pleural mesotheliomaMalignant pleural mesotheliomaJPRN-UMIN000006381agasaki University Hospital32
已完成
不适用
Phase II Study of Amrubicin in Patients with Non-Small Cell Lung Cancer Previously Treated with Platinum-Based ChemotherapyAll patients had histologocally or cytologically confirmed locally advanced (non-irradiated) or metastatic NSCLC, with failure of platinum-based chemotherapy (exception for UFT and gefitinib).JPRN-C000000071West Japan Oncology Group60
已完成
2 期
Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000002570ational Hospital Organization Nagoya Medical Center43
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
已完成
2 期
Phase 2 Study of Amrubicin for patients with recurrent advanced squamous cell lung cancer after first line treatment.Recurrent squamous cell lung cancerJPRN-UMIN000006270Kansai Medical University Hirakata Hospital40